Company Information
Industry 制造业
Company Introduction 公司深耕生物制药全产业链,立足本土,面向全球,依托自主核心技术平台开发创新药和生物类似药,聚焦肿瘤、自身免疫、眼科等重大疾病领域。秉持“创新只为生命”理念,有序推进管线迭代、产能扩张与全球商业化落地,持续为全球患者提供安全、高效、可负担的治疗药物。 公司是一家以创新药和生物类似药研发为核心的创新型生物制药企业,主营业务为药物的研发、生产和销售,拥有独立完整的研发、生产和商业化体系。 在生物类似药领域,公司已成功推动5款药品(阿达木单抗、贝伐珠单抗、托珠单抗、乌司奴单抗、戈利木单抗)实现海内外上市,并有多款生物类似药处于上市审批阶段或关键临床研究阶段。公司已与多家国际知名药企就多个产品达成授权许可协议,产品商业化网络已覆盖美国、欧洲、东南亚、拉丁美洲等全球百余国家及地区。 通过充分应用自身的核心技术,公司获得了多项“十二五”“十三五”国家重大新药创制科技重大专项立项支持;被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业、广东省科技进步奖二等奖。 公司累计提交专利申请44项;获得专利授权9项;截至2026年6月30日,公司拥有已授权的境内外专利88项,282项待审批专利申请,覆盖中国、中国香港、中国澳门、中国台湾、世界知识产权组织(PCT)、美国、欧洲专利局(EP)、澳大利亚、加拿大、日本、新西兰、以色列、墨西哥、新加坡和卢森堡。
Main Business 创新药和生物类似药研发、生产和销售。
Legal Representative 李胜峰
Top Executives
董事长:李胜峰
董事:李胜峰,黄贤明,包财,陈奕藩,王朝禾
独立董事:廖健,柳建华,陈旻湖
Top 5 Shareholder
Shareholder name Nature Holding Date
广州七喜集团有限公司流通A股38.64%30/09/2026
Therabio International Limited流通A股11.39%30/09/2026
广州兴奥启企业管理合伙企业(有限合伙)流通A股5.60%30/09/2026
广州中科粤创孵化器投资管理有限公司-广州中科粤创三号创业投资合伙企业(有限合伙)流通A股5.15%30/09/2026
广州常昱企业管理合伙企业(有限合伙)流通A股3.86%30/09/2026
Company Secretary 鱼丹
Solicitors 北京市君合律师事务所
Auditors 天健会计师事务所(特殊普通合伙);安永华明会计师事务所(特殊普通合伙)
Tel No 020-32203528
Fax No 8620-32203218
Website www.bio-thera.com
Email IR@bio-thera.com
Company Address
Register: 广东省广州市黄埔区国际生物岛螺旋二路18号
Office: 广东省广州市国际生物岛螺旋二路18号
Listing Date 21/02/2020
Shares Capital
Shares Capital: 414,080,000
Total A Share: 414,080,000
Listed A Share: 414,080,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.800
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 0.908
Market Capitalization(RMB) 5.863B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.